Advertisement

Real-world treatment of over 1600 Japanese patients with EGFR mutation-positive non-small cell lung cancer with daily afatinib

  • Kazuo TamuraEmail author
  • Toshihiro Nukiwa
  • Akihiko Gemma
  • Nobuyuki Yamamoto
  • Masaya Mizushima
  • Kaori Ochai
  • Rie Ikeda
  • Hisaya Azuma
  • Yoichi Nakanishi
Original Article
  • 232 Downloads

Abstract

Background

This prospective, post-marketing observational study in Japanese patients aimed to evaluate the safety and effectiveness of daily afatinib use in general practice.

Methods

This non-interventional study (NCT02131259) enrolled treatment-naïve and pre-treated patients with inoperable/recurrent EGFR mutation-positive NSCLC, eligible for afatinib treatment as per the afatinib label in Japan. Patients received afatinib at the approved dose (20, 30, 40, or 50 mg/day; physician decision), and were observed following treatment initiation for 52 weeks or until premature discontinuation. Primary endpoint was the incidence of adverse drug reactions (ADRs). Secondary endpoints included ADRs of special interest, and objective response rate (ORR). Post hoc Cox multivariate analyses were used to assess prognostic factors associated with the incidence of ADRs.

Results

1602 patients, at 374 sites (April 2014–March 2015), were included in the analysis; 307 (19%) were aged ≥ 75 years. The most frequently reported ADRs (all/grade 3–4) were diarrhea (78%/15%), rash/acne (59%/6%), stomatitis (31%/4%), and nail effects (38%/4%). Serious ADRs resulting in death occurred in 18 patients (1%). 762 patients (48%) had ≥ 1 afatinib dose reduction and 366 (23%) discontinued due to ADRs; the most common reason for both was diarrhea (8.2% and 6.7%, respectively). ORR was 40.1%.

Conclusions

Real-world treatment of 1602 Japanese patients with afatinib was associated with a predictable ADR profile. Afatinib showed effectiveness in inoperable/recurrent EGFR mutation-positive NSCLC, especially as first-line treatment. As with other EGFR TKIs, prompt management of adverse events is needed in the Japanese population, to reduce serious events and outcomes, including interstitial lung disease.

Keywords

Afatinib EGFRm + NSCLC Japanese patients Real-world data Post-marketing observational study 

Notes

Acknowledgements

The authors would like to thank all the participating physicians; also the Boehringer Ingelheim study monitors, who contacted the physicians to collect the appropriate data and reported to us. We also appreciate the medical writing assistance provided by Christina Jennings, of GeoMed, an Ashfield company, part of UDG Healthcare plc, and generous support given financially by Boehringer Ingelheim during the preparation of this manuscript.

Compliance with ethical standards

Conflict of interest

KT has received honoraria from Eisai, Ono Pharmaceutical, and Kyowa Hakko Kirin, and fees for promotional materials from Ono Pharmaceutical. AG and NY have received honoraria and research funding from Boehringer Ingelheim. YN has received honoraria from Boehringer Ingelheim. MM, RI, and HA are employees of Nippon Boehringer Ingelheim. KO is an employee of EPS Corporation. TN has nothing to disclose.

Data availability

To ensure independent interpretation of clinical study results, Boehringer Ingelheim grants all external authors access to all relevant material, including participant-level clinical study data, and relevant material as needed by them to fulfill their role and obligations as authors under the ICMJE criteria. Furthermore, clinical study documents (e.g. study report, study protocol, statistical analysis plan) and participant clinical study data are available to be shared after publication of the primary manuscript in a peer-reviewed journal and if regulatory activities are complete and other criteria met per the BI Policy on Transparency and Publication of Clinical Study Data: https://trials.boehringer-ingelheim.com/transparency_policy.html. Prior to providing access, documents will be examined, and, if necessary, redacted and the data will be de-identified, to protect the personal data of study participants and personnel, and to respect the boundaries of the informed consent of the study participants. Clinical Study Reports and Related Clinical Documents can be requested via this link: https://trials.boehringer-ingelheim.com/trial_results/clinical_submission_documents.html. All such requests will be governed by a Document Sharing Agreement. Bona fide, qualified scientific and medical researchers may request access to de-identified, analyzable participant clinical study data with corresponding documentation describing the structure and content of the datasets. Upon approval, and governed by a Data Sharing Agreement, data are shared in a secured data-access system for a limited period of 1 year, which may be extended upon request. Researchers should use https://clinicalstudydatarequest.com to request access to study data.

Supplementary material

10147_2019_1439_MOESM1_ESM.docx (13 kb)
Supplementary material 1 (DOCX 12 kb)

References

  1. 1.
    Zhang YL, Yuan JQ, Wang KF et al (2016) The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget 7(48):78985–78993Google Scholar
  2. 2.
    Solca F, Dahl G, Zoephel A et al (2012) Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. J Pharmacol Exp Ther 343(2):342–350CrossRefGoogle Scholar
  3. 3.
    Sequist LV, Yang JC, Yamamoto N et al (2013) Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 31(27):3327–3334CrossRefGoogle Scholar
  4. 4.
    Wu YL, Zhou C, Hu CP et al (2014) Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol 15(2):213–222CrossRefGoogle Scholar
  5. 5.
    Yang JC, Wu YL, Schuler M et al (2015) Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol 16(2):141–151CrossRefGoogle Scholar
  6. 6.
    Kato T, Yoshioka H, Okamoto I et al (2015) Afatinib versus cisplatin plus pemetrexed in Japanese patients with advanced non-small cell lung cancer harboring activating EGFR mutations: subgroup analysis of LUX-Lung 3. Cancer Sci 106(9):1202–1211CrossRefGoogle Scholar
  7. 7.
    Pharmaceuticals and Medical Devices Agency. List of Approved Products. FY2013, 2013. https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html. Accessed 22 Feb 2018
  8. 8.
    Pharmaceuticals and Medical Devices Agency. Review Report: Gilotrif, 2013. https://www.pmda.go.jp/files/000210320.pdf. Accessed 22 Feb 2018
  9. 9.
    Nakagawa K, Kudoh S, Ohe Y et al (2012) Postmarketing surveillance study of erlotinib in Japanese patients with non-small-cell lung cancer (NSCLC): an interim analysis of 3488 patients (POLARSTAR). J Thorac Oncol 7(8):1296–1303CrossRefGoogle Scholar
  10. 10.
    Akamatsu H, Inoue A, Mitsudomi T et al (2013) Interstitial lung disease associated with gefitinib in Japanese patients with EGFR-mutated non-small-cell lung cancer: combined analysis of two Phase III trials (NEJ 002 and WJTOG 3405). Jpn J Clin Oncol 43(6):664–668CrossRefGoogle Scholar
  11. 11.
    Shi L, Tang J, Tong L et al (2014) Risk of interstitial lung disease with gefitinib and erlotinib in advanced non-small cell lung cancer: a systematic review and meta-analysis of clinical trials. Lung Cancer 83(2):231–239CrossRefGoogle Scholar
  12. 12.
    Hotta K, Kiura K, Takigawa N et al (2010) Comparison of the incidence and pattern of interstitial lung disease during erlotinib and gefitinib treatment in Japanese patients with non-small cell lung cancer: the Okayama Lung Cancer Study Group experience. J Thorac Oncol 5(2):179–184CrossRefGoogle Scholar
  13. 13.
    Wu YL, Sequist LV, Tan E-H et al (2018) Afatinib as first-line treatment of older patients with EGFR mutation-positive non-small-cell lung cancer: subgroup analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 trials. Clin Lung Cancer 19(4):e465–e479CrossRefGoogle Scholar
  14. 14.
    Freiwald M, Schmid U, Fleury A et al (2014) Population pharmacokinetics of afatinib, an irreversible ErbB family blocker, in patients with various solid tumors. Cancer Chemother Pharmacol 73(4):759–770CrossRefGoogle Scholar
  15. 15.
    Yang JC, Sequist LV, Zhou C et al (2016) Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials. Ann Oncol 27(11):2103–2110CrossRefGoogle Scholar
  16. 16.
    Halmos B, Tan E-H, Soo RA et al (2019) Impact of afatinib dose modification on safety and effectiveness in patients with EGFR mutation-positive advanced NSCLC: results from a global real-world study (RealGiDo). Lung Cancer 127:103–111CrossRefGoogle Scholar
  17. 17.
    Ando M, Okamoto I, Yamamoto N et al (2006) Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 24(16):2549–2556CrossRefGoogle Scholar
  18. 18.
    Katakami N, Atagi S, Goto K et al (2013) LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both. J Clin Oncol 31(27):3335–3341CrossRefGoogle Scholar

Copyright information

© Japan Society of Clinical Oncology 2019

Authors and Affiliations

  1. 1.General Medical Research Center, School of MedicineFukuoka UniversityFukuokaJapan
  2. 2.Tohoku UniversityMiyagiJapan
  3. 3.Nippon Medical SchoolTokyoJapan
  4. 4.Division of Pulmonology and Medical Oncology, Third Department of Internal MedicineWakayama Medical UniversityWakayamaJapan
  5. 5.Speciality Care Medicine, Medical DivisionNippon Boehringer Ingelheim Co., Ltd.TokyoJapan
  6. 6.PMS Division, Statistics Analysis Department 2EPS CorporationTokyoJapan
  7. 7.Post Marketing Surveillance Group, PharmacovigilanceNippon Boehringer Ingelheim Co., Ltd.TokyoJapan
  8. 8.Research Institute for Diseases of the Chest, Graduate School of Medical SciencesKyusyu UniversityFukuokaJapan

Personalised recommendations